This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AEterna Zentaris, Inc.
Drug Names(s): Cetrorelix pamoate, NS75B, AEZS-102
Description: Cetrotide is an analog of gonadotropin-releasing hormone (GnRH). Cetrotide blocks the action of GnRH and consequently blocks luteinizing hormone (LH), which induces ovulation during the menstrual cycle. Cetrotide has been developed to prevent premature ovulation in women undergoing controlled ovarian stimulation for assisted reproductive technologies (ART).
terna Zentaris and Merck Serono
In 2000, a license agreement between terna Zentaris and Merck Serono was signed, granting Merck Serono exclusive rights to market, distribute and sell Cetrotide worldwide, with the exception of Japan, in the field of in vitro fertilization. This agreement provides the Company, amongst other things, with manufacturing income, royalties on worldwide (except Japan) net sales and fixed annual lump sum payments until 2010. The fixed annual lump sum payments will become double digit royalties on the net worldwide sales of Cetrotide (except Japan) thereafter.
In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.
In April 2013,...See full deal structure in Biomedtracker
Partners: Merck KGaA Shionogi & Co. Ltd.
Additional information available to subscribers only: